Stock Monitor: Iovance Biotherapeutics Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 15, 2017 / Active-Investors issued a free report on BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=BLFS as the Company's latest news hit the wire. On December 13, 2017, the Company declared that it has executed an agreement to supply its CryoStor® cell freeze media and HypoThermosol® cell storage and shipping media to Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance"). Iovance is currently conducting several clinical trials for tumor infiltrating lymphocyte (TIL) therapies targeting multiple solid tumor types. Sign up now for our free research reports at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, BioLife Solutions most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage BLFS and IOVA are available at:
BioLife's Proprietary Bio-Preservation Media Products Being Adopted Due to Improved Yield
Commenting on the collaboration, Mike Rice, President and Chief Executive Officer (CEO) of BioLife, stated that it was very rewarding to see the Company's proprietary bio-preservation media products being broadly adopted in the regenerative medicine market, due to the improved yield and extended shelf life its IP platform can offer to its customers.
BioLife's Long-Term Supply Agreements for CryoStor® Use
CryoStor® and HypoThermosol® have been incorporated into the manufacturing processes of at least 250 regenerative medicine applications, including numerous late-stage clinical trials. Reports suggest that till date, the Company has executed long-term supply agreements with the following Companies:
- On November 29, 2017, the Company executed a new confidential agreement to supply its proprietary CryoStor® cell freeze media to a leading T cell therapy customer.
- In July 2017, BioLife entered into a long-term supply agreement with Celyad. BioLife's CryoStor® clinical grade cell freeze media is incorporated into Celyad's manufacturing process for its Natural Killer Receptor based T-Cell platform.
- The Company entered into a supply agreement with Adaptimmune Therapeutics Plc, for the use of CryoStor® in SPEAR T-Cell Platform, on June 14, 2017.
- In December 2016, BioLife signed a ten-year supply agreement with TissueGene. The former's CryoStor® clinical grade cell freeze media is incorporated into TissueGene's manufacturing process for Invossa.
- The Company entered into a ten-year supply agreement with Bellicum Pharmaceuticals, for CryoStor® use in Cellular Immunotherapies, in August 2016.
- On July 11, 2016, BioLife signed a ten-year supply agreement with Kite Pharma. The agreement provided for Kite's supply of BioLife's CryoStor® clinical grade freeze media for cells and tissues, which is embedded in Kite's manufacturing process for KTE-C19.
- In June 2014, Nice, France-based TxCell, adopted BioLife's CryoStor® clinical grade cell freezing media for use in their European Phase-IIb clinical trial of Ovasave immunotherapy in refractory Crohn's Disease.
About CryoStor® Cell Freeze Media and HypoThermosol® Cell Storage
CryoStor® cryopreservation freeze media products have been designed to mitigate temperature-induced molecular cell stress responses during freezing and thawing, and are based on the novel HypoThermosol® formula. These products have proven to be much more effective in reducing post-preservation necrosis and apoptosis compared to commercial and home-brew isotonic and extracellular formulations.
HypoThermosol® bio-preservation media is a novel, engineered, optimized hypothermic storage and shipping media product. Serum-free, protein-free HypoThermosol® is designed to provide maximum storage and shipping stability for biologics at 2-8°C. This proprietary, optimized formulation mitigates temperature-induced molecular cell stress responses that occur during chilling and re-warming of biologics, intermediate products, and final cell products intended for research and clinical applications.
About BioLife Solutions, Inc.
Founded in 1987, BioLife is a leading developer, manufacturer, and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, and a related cloud hosted bio-logistics cold chain management app for smart shippers. The Company is based in Bothell, Washington.
About Iovance Biotherapeutics, Inc.
Established in 2007 and headquartered in San Carlos, California, Iovance is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company's lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.
Stock Performance Snapshot
December 14, 2017 - At Thursday's closing bell, BioLife Solutions' stock climbed 3.72%, ending the trading session at $5.85.
Volume traded for the day: 60.56 thousand shares.
Stock performance in the last three-month – up 20.62%; previous six-month period – up 156.58%; past twelve-month period – up 272.61%; and year-to-date - up 263.29%
After yesterday's close, BioLife Solutions' market cap was at $77.57 million.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.